- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
Patent holdings for IPC class A61K 31/573
Total number of patents in this class: 4428
10-year publication summary
|
368
|
382
|
412
|
397
|
414
|
414
|
423
|
376
|
311
|
87
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Chiesi Farmaceutici S.p.A. | 964 |
61 |
| Janssen Biotech, Inc. | 1659 |
55 |
| Genentech, Inc. | 4065 |
53 |
| The Regents of the University of California | 20502 |
41 |
| Celgene Corporation | 1390 |
34 |
| Sage Therapeutics, Inc. | 341 |
31 |
| Janssen Pharmaceutica N.V. | 3262 |
28 |
| Regeneron Pharmaceuticals, Inc. | 4573 |
25 |
| Hoffmann-La Roche Inc. | 3659 |
24 |
| The Board of Trustees of the Leland Stanford Junior University | 6605 |
24 |
| Allergan, Inc. | 2234 |
23 |
| Cassiopea S.P.A. | 52 |
23 |
| AVM Biotechnology, LLC | 25 |
21 |
| Mexichem Fluor, Sociedad Anonima de Capital Variable | 203 |
21 |
| ReveraGen Biopharma, Inc. | 33 |
21 |
| Oculis Operations Sàrl | 41 |
21 |
| Massachusetts Institute of Technology | 10185 |
20 |
| Antecip Bioventures II LLC | 353 |
20 |
| Bristol-myers Squibb Company | 4821 |
19 |
| Chugai Seiyaku Kabushiki Kaisha | 1391 |
19 |
| Other owners | 3844 |